Updated on 14 December 2012
Dr Steven Fang, founder and CEO of Cordlife, will join Clearbridge Accelerator as a partner from Jan 1
Singapore: Dr Steven Fang has joined Clearbridge Accelerator, a leading technology incubator based in Singapore, as a partner. Dr Fang's entrepreneurial and business experience within the biomedical sector, together with his extensive linkages across Asia will expand Clearbridge Accelerator's capabilities and networks.
Prior to this, Dr Fang was the CEO of Cordlife Limited (CBB), which demerged from Cordlife Group Limited (CGL) in June 2011 and is listed in Australia.
Dr Fang will officially join Clearbridge Accelerator on January 1, 2013. Dr Fang's responsibility will include providing direction to incubatee companies in order to support the commercial translation of their technologies into globally-marketable products, as well as mentorship and helping to raise necessary funds.
"I am delighted to be part of the Clearbridge Accelerator team, having always enjoyed the dynamism of working with biomedical start-ups. I will leverage on this experience and together with Clearbridge's progressive track record and funding strength I hope to work with the team to create the next generation of successful global medical and life sciences companies. I will be focusing on growing their portfolio of investee companies and in exploring relevant growth and exit opportunities to this end," said Dr Fang.
"We are very excited to welcome Steven to Clearbridge Accelerator, as a full-time partner. He will undoubtedly add tremendous value to boost the performance of the technology incubator, as well as support our incubatee companies to grow and expand into international markets. Steven's joining Clearbridge Accelerator is in line with our vision to establish the company as the premier medical technology accelerator," said Mr Johnson Chen, managing partner, Clearbridge Accelerator.
Clearbridge Accelerator is supported by the National Research Foundation's Technology Incubation Scheme and is also a recipient of SPRING Singapore's Biomedical Sciences Accelerators (BSA) programme.